|By PR Newswire||
|August 19, 2014 08:15 AM EDT||
JERUSALEM, August 19, 2014 /PRNewswire/ --
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Intellectual Property Department of Spain has granted the Company's patent for its invention, titled "Methods and Compositions for Oral Administrations of Proteins."
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (POD[TM]) technology is based on over 30 years of research by top scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). Having completed separate Phase IIa clinical trials, the company anticipates the initiation of separate Phase IIb clinical trials, in patients with both type 1 and type 2 diabetes under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition the company is developing an oral GLP-1 analog capsule (ORMD-0901).
For more information, the content of which is not part of this press release, please visithttp://www.oramed.com
Forward-looking statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, we are using forward-looking statements when we discuss our clinical trials, including the expected timing thereof, and revolutionizing the treatment of diabetes with our products. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.
Office: +972-2-566-0001 ext. 2
US: +1-718-831-2512 ext. 2
Email: [email protected]
US Investor Relations Contact:
Anne Marie Fields
Senior Vice President
Email: [email protected]
SOURCE Oramed Pharmaceuticals Inc.
Oct. 25, 2016 04:45 PM EDT Reads: 1,539
Oct. 25, 2016 04:15 PM EDT Reads: 1,436
Oct. 25, 2016 03:28 PM EDT Reads: 227
Oct. 25, 2016 03:15 PM EDT Reads: 378
Oct. 25, 2016 03:00 PM EDT Reads: 34,197
Oct. 25, 2016 03:00 PM EDT Reads: 2,012
Oct. 25, 2016 02:30 PM EDT Reads: 1,472
Oct. 25, 2016 02:15 PM EDT Reads: 2,657
Oct. 25, 2016 01:45 PM EDT Reads: 1,257
Oct. 25, 2016 01:30 PM EDT Reads: 2,695
Oct. 25, 2016 01:15 PM EDT Reads: 1,058
Oct. 25, 2016 12:45 PM EDT Reads: 4,949
Oct. 25, 2016 12:30 PM EDT Reads: 8,484
Oct. 25, 2016 12:00 PM EDT Reads: 2,690
The Internet of Things will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform and how we integrate our thinking to solve complicated problems. In his session at 19th Cloud Expo, Craig Sproule, CEO of Metavine, will demonstrate how to move beyond today's coding paradigm ...
Oct. 25, 2016 11:45 AM EDT Reads: 3,817